# Prodrug
A prodrug is a pharmacologically inactive or weakly active derivative of an active drug that undergoes biotransformation in the body, by enzymatic or chemical cleavage or a combination of the two, to release the active parent drug[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6989223/). The IUPAC definition states that a prodrug is a compound that undergoes biotransformation before exhibiting pharmacological effects[2](https://sciendo.com/2/v2/download/article/10.1515/amma-2016-0032.pdf). The Merck Manual adds the design intent: an inactive or weakly active substance with an active metabolite is called a prodrug especially when it is specifically designed to deliver the active moiety more effectively[3](https://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/drug-metabolism).
| Key fact | Detail |
|---|---|
| Definition | A bioreversible derivative of an active drug that undergoes an enzymatic and/or chemical transformation in vivo to release the parent drug[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281) |
| Origin of the term | Introduced by Adrien Albert in 1958; he later said "predrug" would have been more descriptive, but the term was too widely used to change[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281) |
| Earliest intentional example | Methenamine (hexamine), introduced in 1899[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281) |
| Prevalence | In the 10 years before 2018 the FDA approved at least 30 prodrugs, more than 12% of all approved small-molecule new chemical entities[5](https://pubmed.ncbi.nlm.nih.gov/29700501/); about 20% of small-molecular drugs approved from 2000 to 2008 were prodrugs[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281) |
| Design goals | Increased solubility, enhanced stability, improved bioavailability, reduced side effects, and better selectivity[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645) |
| Activation routes | Enzyme-mediated hydrolytic or oxidoreductive processes, or purely chemical nonenzymatic processes[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645) |
| Clinical examples | Oseltamivir (anti-influenza), enalapril (anti-hypertension), capecitabine (cancer), omeprazole (peptic ulcer)[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645) |
## History
Adrien Albert, an Australian chemist, first introduced the term "pro-drug" in 1958. A few decades later he apologized for having invented such an inaccurate term, saying "predrug" would have been more descriptive, but by then the original version was too widely used to change[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281). The concept itself predates the name: the first intentionally designed prodrug is most probably methenamine, introduced in 1899[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281). Early prodrugs also include the antibacterial methenamine and the anti-inflammatory aspirin (acetylsalicylic acid), launched by Schering and Bauer respectively[7](https://pubs.rsc.org/en/content/articlepdf/2025/md/d4md00788c).
Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed, in order to avoid development challenges that limit formulation options or produce unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting[5](https://pubmed.ncbi.nlm.nih.gov/29700501/).
## Why prodrugs are used
A prodrug strategy is typically used when a pharmacologically active drug has poor solubility or permeability; chemically or enzymatically labile functional groups are introduced to improve the properties of the parent drug and decrease presystemic metabolism[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6989223/). The underlying goal is to conceal unwanted characteristics of a drug, including poor solubility in water or lipid membranes, poor selectivity for its target, chemical instability, unpleasant taste, irritation or pain when administered locally, presystemic metabolism, and toxicity.[8](https://www.sciencedirect.com/science/article/pii/S1734114013709599)
Clinically, the majority of prodrugs have been used with the aim of enhancing drug permeation by increasing lipophilicity, and more recently to improve water solubility[9](https://doi.org/10.1038/NRD2468). Modern prodrugs also incorporate cellular and molecular parameters to accomplish site-specificity, targeting organs, tissues, enzymes, or transporters[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC7692606/).
**A quantitative example.** Valacyclovir, the 5'-valyl ester prodrug of the antiviral acyclovir, increased the oral bioavailability of its parent drug by 3- to 5-fold, attributable to carrier-mediated intestinal transport of the prodrug by the peptide transporter PEPT1[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6271014/).
## Activation mechanisms
A key step in prodrug design is incorporating an activation mechanism that converts the prodrug into the active species efficiently or in a controlled manner suited to the medical application[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645). Activation can proceed through enzyme-mediated hydrolytic or oxidoreductive processes, while some prodrugs are activated by purely chemical nonenzymatic processes[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645). Activation is usually via enzymatic processes such as those by cytochrome enzymes, esterases, and amidases, or chemical processes such as hydrolysis and oxidation[12](https://www.mdpi.com/1420-3049/25/4/884/pdf?version=1582107256).
Important enzymes in the activation and bioconversion of ester-based prodrugs include paraoxonase, carboxylesterase, acetylcholinesterase, and cholinesterase[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6271014/). Hydrolytic enzymes used in prodrug activation span transferases, hydrolases, and lyases[6](https://www.sciencedirect.com/science/article/pii/S2211383511000645).
Knowledge of the activating enzyme has become a design tool in itself. The mechanism of activation was often overlooked in the past, as long as the free parent drug was liberated; it is now well recognized that substantial knowledge of the activating enzymes can aid rational prodrug design, and identifying them provides new targets for designing effective therapeutic agents[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6271014/). For example, human valacyclovirase was shown to be an optimal targeting molecule for α-amino acid ester prodrugs, while it is only mildly active toward amide prodrugs[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC7692606/).
## Classification
One proposed regulatory classification divides prodrugs by the cellular location of conversion. Type I prodrugs convert intracellularly, in metabolic tissues such as the liver (Type IA) or at therapeutic target cells (Type IB). For Type II prodrugs, conversion takes place extracellularly in gastrointestinal fluids (Type IIA), in the systemic circulation or other systemic extracellular fluid compartments (Type IIB), or near therapeutic target cells (Type IIC). A prodrug may belong to multiple categories and be recognized as a Mixed-Type prodrug, further distinguished as Parallel Mixed-Type or Sequential Mixed-Type depending on whether the conversion processes proceed concurrently or sequentially[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC3978533/).
A related structural distinction separates carrier-linked prodrugs, in which the active molecule is temporarily linked to a carrier (a promoiety) through a bioreversible covalent linkage, from prodrugs that lack an obvious carrier or promoiety and instead result from a molecular modification of the drug itself that generates a new active compound[8](https://www.sciencedirect.com/science/article/pii/S1734114013709599) • [4](https://www.sciencedirect.com/science/article/pii/S0031699724009281).
## Prevalence and market impact
Prodrugs form a substantial share of approved small-molecule drugs. About 5–7% of drugs approved worldwide can be classified as prodrugs[9](https://doi.org/10.1038/NRD2468). Approximately 20% of all small molecular drugs approved during 2000 to 2008 were prodrugs[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281), and during 2008–2017, 12.4% of all new molecular entities approved by the FDA were prodrugs, 31 out of 249[12](https://www.mdpi.com/1420-3049/25/4/884/pdf?version=1582107256). In the 10 years before 2018, the FDA approved at least 30 prodrugs, accounting for more than 12% of all approved small-molecule new chemical entities[5](https://pubmed.ncbi.nlm.nih.gov/29700501/).
## Challenges
Prodrug development carries risks despite its benefits, including chemical stability and specificity[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC4627459/). Activation specificity is a significant challenge: enzyme-responsive prodrugs require meticulous optimization of enzymes and their substrates, and although linker chemical bonds are generally less susceptible to physiological conditions, lowering the risk of non-specific activation, the possibility of premature or failed activation at incorrect sites remains[15](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1434137/full). Problems can also arise from inadequate activation of the prodrug in vivo[4](https://www.sciencedirect.com/science/article/pii/S0031699724009281).
Because metabolism rates vary among patients, with individual rates influenced by genetic factors, coexisting disorders, and drug interactions, the activation of a prodrug can differ between patients; some patients metabolize drugs so rapidly that effective concentrations are not reached, while in others metabolism is so slow that usual doses have toxic effects[3](https://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/drug-metabolism).
## References
1. [Understanding the pharmacokinetics of prodrug and metabolite, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6989223/)
2. [Prodrug design review, Acta Medica Marisiensis 2016](https://sciendo.com/2/v2/download/article/10.1515/amma-2016-0032.pdf)
3. [Drug Metabolism, Merck Manual Professional Edition](https://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/drug-metabolism)
4. [Prodrugs—from Serendipity to Rational Design, ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0031699724009281)
5. [The expanding role of prodrugs in contemporary drug design and development, PubMed](https://pubmed.ncbi.nlm.nih.gov/29700501/)
6. [Enzyme-mediated hydrolytic activation of prodrugs, Acta Pharmaceutica Sinica B](https://www.sciencedirect.com/science/article/pii/S2211383511000645)
7. [CNS prodrug activation tools, RSC Medicinal Chemistry](https://pubs.rsc.org/en/content/articlepdf/2025/md/d4md00788c)
8. [Prodrugs: A challenge for the drug development, ScienceDirect](https://www.sciencedirect.com/science/article/pii/S1734114013709599)
9. [Prodrugs: design and clinical applications, Nature Reviews Drug Discovery](https://doi.org/10.1038/NRD2468)
10. [Prodrugs for Improved Drug Delivery, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7692606/)
11. [Modern Prodrug Design for Targeted Oral Drug Delivery, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6271014/)
12. [Newly Developed Prodrugs, Molecules (MDPI)](https://www.mdpi.com/1420-3049/25/4/884/pdf?version=1582107256)
13. [A New Classification of Prodrugs: Regulatory Perspectives, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3978533/)
14. [Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4627459/)
15. [Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment, Frontiers in Pharmacology](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1434137/full)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Pharmacology and drug action › Pharmacokinetics and drug metabolism*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license